FDA warning letter citing over-reliance on AI in CGMP operations (Purolea Cosmetics Lab)

Context and history

FDA issued this warning letter (320-26-58) to Purolea Cosmetics Lab on 2 April 2026, after inspecting the site from 28 to 30 October 2025. It cites significant CGMP violations. It has a section headed Inappropriate Use of Artificial Intelligence in Pharmaceutical Manufacturing, saying the firm told investigators it used AI agents to help it comply, and used AI to create specifications, procedures and master production or control records. A warning letter concerns one firm, but it shows how FDA thinks about AI output.

FDA's words on the facts are specific. The firm's response to a process validation finding was that it had not known of the requirement, because the AI agent had not told it. FDA records this as an example of overreliance. The firm has ceased drug production, and FDA adds that if it resumes and uses AI for CGMP activities, any AI output must be reviewed and cleared by an authorised human representative of the quality unit.

Who and what it applies to

This one firm. It is a record of enforcement, not guidance for everyone.

What it contains

CGMP findings

Violations under parts 210 and 211, and unapproved new drug findings. See the letter for each one.

Inappropriate use of AI

FDA says that if AI is an aid in document creation, the firm must review its documents to confirm they are accurate and CGMP-compliant, and that failing to do so violates 21 CFR 211.22(c).

Overreliance example

No process validation before distribution, as required by 21 CFR 211.100. The firm said the AI agent never told it this was required.

If production resumes

AI output must be reviewed and cleared by an authorised human representative of the quality unit, under section 501(a)(2)(B) of the FD&C Act.

Key points

• AI output in CGMP documents must be reviewed by the quality unit.
• Lack of knowledge is no defence, even where an AI tool was the source of advice.
• The legal hooks are existing rules: 211.22 and 211.100. No new AI rule was needed.
• It binds one firm, and it shows how FDA reads existing rules.

In practice

General reading, not advice. This is drafted with AI and may not fit your situation. It does not replace the official text, your own quality system or qualified advice, and an inspector may take a different view.

• Record who reviewed and approved any AI-drafted specification, procedure or master record.
• Make sure your quality unit, not the tool, knows which CGMP requirements apply.
• Do not treat an AI tool's silence as evidence that nothing is required.
• Add AI use to your procedure for document creation, and train reviewers on it.

Read from the source document on 1 Nov 2026. This is our own description, not the official text. Check the full dated history in the change log below.